# EDGAR Filing Document

**Accession Number:** 0001840877
**File Stem:** 0001213900-26-068305
**Filing Date:** 2026-6
**Character Count:** 26547
**Document Hash:** c8700806544ba178ee843edfe555a515
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-068305.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001213900-26-068305

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260612

**DATE AS OF CHANGE**: 20260612

**EFFECTIVENESS DATE**: 20260612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Envoy Medical, Inc.
- **CENTRAL INDEX KEY:** 0001840877
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 861369123
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-296753
- **FILM NUMBER:** 261087273

**BUSINESS ADDRESS:**
- **STREET 1:** 4875 WHITE BEAR PARKWAY
- **CITY:** WHITE BEAR LAKE
- **STATE:** MN
- **ZIP:** 55110
- **BUSINESS PHONE:** 651-361-8000

**MAIL ADDRESS:**
- **STREET 1:** 4875 WHITE BEAR PARKWAY
- **CITY:** WHITE BEAR LAKE
- **STATE:** MN
- **ZIP:** 55110

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Anzu Special Acquisition Corp I
- **DATE OF NAME CHANGE:** 20210115

**As filed with the Securities and Exchange Commission on June 12, 2026**

**Registration No. 333-** 

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**FORM S-8<br> REGISTRATION STATEMENT<br> *UNDER<br> THE SECURITIES ACT OF 1933***

**ENVOY MEDICAL, INC.<br> (Exact Name of Registrant as Specified in Its Charter)**

---

| | |
|:---|:---|
| **Delaware** | **86-1369123** |
| **(State or Other Jurisdiction of<br> Incorporation or Organization)** | **(I.R.S. Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **4875 White Bear Parkway<br> White Bear Lake, Minnesota** | **55110** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Envoy Medical, Inc. Amended and Restated 2023 Equity Incentive Plan<br> Envoy Medical, Inc. 2023 Employee Stock Purchase Plan<br> (Full Title of the Plan)**

**Brent T. Lucas<br> Chief Executive Officer<br> Envoy Medical, Inc.<br> 4875 White Bear Parkway<br> White Bear Lake, Minnesota 55110<br> (Name and Address of Agent for Service)**

**(877) 900-3277<br> (Telephone Number, including area code, of agent for service)**

 ****

***Copies to:*<br> Andrew M. Nick<br> Fredrikson & Byron, P.A.<br> 60 South Sixth Street; Suite 1500<br> Minneapolis, MN 55402<br> (612) 492-7000**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**PART I<br> INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1. Plan Information.**

Information required by this Item 1 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the "Securities Act") and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the "Commission") and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**Item 2. Registrant Information and Employee Plan Annual Information.**

Information required by this Item 2 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

**PART II<br> INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents, which have been filed by Envoy Medical, Inc. (the "Registrant") with the Commission, are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;(i) the Registrant's Annual Report on [Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1840877/000121390026032683/ea0280884-10k_envoy.htm) for the fiscal
 year ended December 31, 2025, filed with the Commission on March 23, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;(ii) the Registrant's Current Reports on Form 8-K (other than information
 furnished rather than filed), filed with the Commission on [March 31, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1840877/000121390026037419/ea0283875-8k_envoy.htm) , [April 21, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1840877/000121390026046197/ea028718601-8k_envoymedical.htm) , [May 11, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1840877/000121390026054185/ea0289965-8k_envoy.htm) , and [May 18, 2026](http://www.sec.gov/ix?doc=/Archives/edgar/data/1840877/000121390026058429/ea0291354-8k_envoy.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;(iii) the description of the Registrant's Common Stock which is
 contained in a registration statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1840877/000110465921029657/tm213438d9_8a12b.htm) filed on March 1, 2021 (File No. 001-40133)
 under the Exchange Act, as updated by [Exhibit 4.3](https://www.sec.gov/Archives/edgar/data/1840877/000121390024028894/ea020296601ex4-3_envoy.htm) to the Registrant's Annual Report
 on [Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1840877/000121390024028894/ea0202966-10k_envoy.htm) for the year ended December 31, 2023, filed with the Commission on April 1,
 2024, as well as any additional amendments or reports filed for the purpose of updating such
 description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such documents, except as to specific sections of such statements as set forth therein.

Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

**Item 4. Description of Securities**.

Not applicable.

**Item 5. Interests of Named Experts and Counsel**.

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

The Registrant's second amended and restated certificate of incorporation contains provisions that limit the liability of the Registrant's directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, the Registrant's directors will not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:

● for any breach of their duty of loyalty to the Registrant or its stockholders;

● for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

● unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

● for any transaction from which they derived an improper personal benefit.

The Registrant's amended and restated bylaws provide that the Registrant shall indemnify, to the fullest extent permitted by law, any person who is or was a party or is threatened to be made a party to any action, suit or proceeding, by reason of the fact that he or she is or was one of the Registrant's directors or officers or is or was serving at the Registrant's request as a director or officer of another corporation, partnership, joint venture, trust, non-profit entity or other enterprise. The Registrant's amended and restated bylaws provide that the Registrant may indemnify the Registrant's employees or agents. The Registrant's amended and restated bylaws also provide that the Registrant must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions.

The Registrant maintains insurance policies under which, subject to the limitations of the policies, coverage is provided to its directors and officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or officer, including claims relating to public securities matters, and to the Registrant with respect to payments that may be made by the Registrant to these officers and directors pursuant to the Registrant's indemnification obligations or otherwise as a matter of law.

The Registrant entered into indemnification agreements with each of its directors and executive officers that are broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements require the Registrant, among other things, to indemnify the Registrant's directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant's company pursuant to the foregoing provisions, the Registrant has been informed that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

**Item 7. Exemption from Registration Claimed**.

Not applicable.

**Item 8. Exhibits**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| <br>**Exhibit<br> Number** | <br>**Description** | **Schedule/<br> Form** | **File No.** | **Exhibit** | **Filing<br> Date** |
| 4.1 | [Second Amended and Restated Certificate of Incorporation of Envoy Medical, Inc. (f/k/a Anzu Special Acquisition Corp I).](https://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex3-1_envoy.htm) | 8-K | 001-40133 | 3.1 | October 5, 2023 |
| 4.2 | [Amended and Restated Bylaws of Envoy Medical, Inc.](https://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex3-2_envoy.htm) | 8-K | 001-40133 | 3.2 | October 5, 2023 |
| 4.3 | [Certificate of Designation of Series A Preferred Stock of Envoy Medical, Inc.](https://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex3-3_envoy.htm) | 8-K | 001-40133 | 3.3 | October 5, 2023 |
| 5.1\* | [Opinion of Fredrikson & Byron, P.A.](ea029336601ex5-1.htm) |  |  |  |  |
| 23.1\* | [Consent of Grant Thornton LLP, independent registered public accounting firm of Envoy Medical, Inc.](ea029336601ex23-1.htm) |  |  |  |  |
| 23.2\* | [Consent of Fredrikson & Byron, P.A. (filed as part of Exhibit 5.1).](ea029336601ex5-1.htm) |  |  |  |  |
| 24.1\* | [Power of Attorney (filed as part of signature page).](#a_013) |  |  |  |  |
| 99.1 | [Envoy Medical, Inc. Amended and Restated Equity Incentive Plan 2023 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1840877/000121390025050758/ea024441801ex10-1_envoy.htm) | 8-K | 001-40133 | 10.1 | June 3, 2025 |
| 99.2 | [Envoy Medical, Inc. 2023 Employee Stock Purchase Plan.](https://www.sec.gov/Archives/edgar/data/1840877/000101376223002246/ea186352ex10-23_envoy.htm) | 8-K | 001-40133 | 10.23 | October 5, 2023 |
| 99.3 | [Amendment No. 1 to Envoy Medical, Inc. Amended and Restated Equity Incentive Plan 2023 Equity Incentive Plan](https://www.sec.gov/Archives/edgar/data/1840877/000121390026058429/ea029135401ex10-1.htm). | 8-K | 001-40133 | 10.1 | May 18, 2026 |
| 99.4 | [Amendment No. 1 to Envoy Medical, Inc. 2023 Employee Stock Purchase Plan](https://www.sec.gov/Archives/edgar/data/1840877/000121390026058429/ea029135401ex10-2.htm). | 8-K | 001-40133 | 10.2 | May 18, 2026 |
| 107\* | [Filing Fee Table.](ea029336601ex-fee.htm) |  |  |  |  |

---

\* Filed herewith.

**Item 9. Undertakings**.

a. The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made,
 a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities
 Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the
 effective date of the Registration Statement (or the most recent post-effective amendment
 thereof) which, individually or in the aggregate, represent a fundamental change in the information
 set forth in the Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of
 distribution not previously disclosed in the Registration Statement or any material change
 to such information in the Registration Statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by such paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities
 Act, each such post-effective amendment shall be deemed to be a new registration statement
 relating to the securities offered therein, and the offering of such securities at that time
 shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment
 any of the securities being registered which remain unsold at the termination of the offering.

b. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under
 the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or
 Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's
 annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the
 Registration Statement shall be deemed to be a new registration statement relating to the securities
 offered therein, and the offering of such securities at that time shall be deemed to be the initial
 bona fide offering thereof.

c. Insofar as indemnification for liabilities arising under the Securities
 Act may be permitted to directors, officers and controlling persons of the Registrant pursuant
 to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion
 of the Commission such indemnification is against public policy as expressed in the Securities
 Act and is, therefore, unenforceable. In the event that a claim for indemnification against
 such liabilities (other than the payment by the Registrant of expenses incurred or paid by
 a director, officer or controlling person of the Registrant in the successful defense of
 any action, suit or proceeding) is asserted by such director, officer or controlling person
 in connection with the securities being registered hereby, the Registrant will, unless in
 the opinion of its counsel the matter has been settled by controlling precedent, submit to
 a court of appropriate jurisdiction the question whether such indemnification by it is against
 public policy as expressed in the Securities Act and will be governed by the final adjudication
 of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of White Bear Lake, State of Minnesota, on June 12, 2026.

---

| | |
|:---|:---|
| **Envoy Medical, Inc.** | **Envoy Medical, Inc.** |
| By: | /s/ Brent T. Lucas |
| Name: | Brent T. Lucas |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS**, that the undersigned officers and directors of Envoy Medical, Inc., a Delaware corporation, do hereby constitute and appoint Brent T. Lucas and Robert M. Potashnick, and each of them, the lawful attorneys-in-fact and agents with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Brent T. Lucas | Chief Executive Officer and Director | June 12, 2026 |
| Brent T. Lucas | (Principal Executive Officer) |  |
| /s/ Robert M. Potashnick | Chief Financial Officer | June 12, 2026 |
| Robert M. Potashnick | (Principal Financial and Accounting Officer) |  |
| /s/ Charles R. Brynelsen | Director | June 12, 2026 |
| Charles R. Brynelsen |  |  |
| /s/ Michael Crowe | Director | June 12, 2026 |
| Michael Crowe |  |  |
| /s/ Mona Patel | Director | June 12, 2026 |
| Mona Patel |  |  |
| /s/ Charles S. McKhann | Director | June 12, 2026 |
| Charles S. McKhann |  |  |
| /s/ Janis Smith-Gomez | Director | June 12, 2026 |
| Janise Smith-Gomez |  |  |
| /s/ Susan J. Kantor | Director | June 12, 2026 |
| Susan J. Kantor |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ea029336601_ex5-1img1.jpg)

June 12, 2026

Board of Directors<br> Envoy Medical, Inc.\|<br> 4875 White Bear Lake Parkway<br> White Bear Lake, MN 55110

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

We are acting as counsel to Envoy Medical, Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the filing of a Registration Statement on Form S-8 (the "<u>Registration Statement</u>") with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the "<u>Securities Act</u>") covering the offering of up to an aggregate of 7,200,000 shares (the "<u>Shares</u>") of the Company's Class A common stock, $0.0001 par value per share (the "<u>Class A Common Stock</u>"), consisting of (i) up to 6,000,000 shares of Class A Common Stock issuable pursuant to the Envoy Medical, Inc. Amended and Restated 2023 Equity Incentive Plan, as amended (the "<u>2023 Incentive Plan</u>"), and (ii) up to 1,200,000 shares of Class A Common Stock issuable pursuant to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan, as amended(the "<u>2023 ESPP</u>" and, together with the 2023 Incentive Plan, the "<u>Plans</u>").

As counsel for the Company, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary for the purposes of rendering this opinion, and we are familiar with the proceedings taken and proposed to be taken by the Company in connection with the authorization, issuance and sale of the Shares. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity with the originals of all documents submitted to us as copies. This opinion letter is given, and all statements herein are made, in the context of the foregoing.

This opinion letter is based as to matters of law solely on the General Corporation Law of the State of Delaware as currently in effect. We express no opinion herein as to any other laws, statutes, ordinances, rules, or regulations.

Based upon, subject to and limited by the foregoing, we are of the opinion that following (i) effectiveness of the Registration Statement, (ii) issuance of the Shares pursuant to awards under the terms of the Plans, and (iii) receipt by the Company of the consideration for the Shares specified in the applicable resolutions of the Board of Directors of the Company or a duly authorized committee thereof and the Plans, the Shares will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion letter has been prepared for use in connection with the Registration Statement. We assume no obligation to advise you of any changes in the foregoing subsequent to the effective date of the Registration Statement.

We consent to the filing of this opinion as an exhibit to the Registration Statement, and we consent to the reference of our name wherever appearing in the Registration Statement and any amendments thereto. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

---

| |
|:---|
| Very truly yours, |
| /s/ Fredrikson & Byron, P.A. |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated March 23, 2026 with respect to the consolidated financial statements of Envoy Medical, Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2025, which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement.

---

| |
|:---|
| /s/ GRANT THORNTON LLP |
| Fort Lauderdale, Florida |
| June 12, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**Envoy Medical, Inc.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Class A Common Stock, $0.0001 par value per share | (1) | Other | 7200000 | $0.67 | $4824000.00 | 0.0001381 | $666.19 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $4824000.00 |  | 666.19 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $666.19 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from share splits, share dividends or similar transactions. Represents (i) up to 6,000,000 shares of Envoy Medical Inc.'s Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), reserved for issuance under the Envoy Medical, Inc. Amended and Restated 2023 Equity Incentive Plan, as amended, and (ii) up to 1,200,000 shares of Class A Common Stock reserved for issuance under the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan, as amended. Pursuant to Rules 457(c) and (h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $0.67, which is the average of the high and low prices of the Class A Common Stock on June 8, 2026 on the Nasdaq Capital Market.